A new gene silencing platform -- silence is golden

Feb 08, 2009

A team of researchers led by Rutgers' Samuel Gunderson has developed a novel gene silencing platform with very significant improvements over existing RNAi approaches. This may enable the development and discovery of a new class of drugs to treat a wide array of diseases. Critical to the technology is the approach this team took to specifically target RNA biosynthesis.

The research findings are reported in the journal Nature Biotechnology, published online in the February 8th issue.

Gunderson, an associate professor in the Department of Molecular Biology and Biochemistry at Rutgers, The State University of New Jersey, has created highly efficient gene silencing agents that function via a novel mechanism of action. The agents are single-stranded oligonucleotides, called U1 Adaptors, that have dual, and independent, functions. First is a target-gene binding domain that can be tailored to any gene. The second domain inhibits mRNA maturation by binding U1 snRNP, a component of the cellular splicing apparatus.

By combining both capabilities in the same molecule, the U1 Adaptor can inhibit the pre-mRNA maturation step of polyA tail addition in a gene specific manner. Further, the domains of the oligonucleotide are independent so transcript binding and U1 snRNP binding can be independently optimized and adapted to a wide array of genes associated with disease.

"The U1 Adaptor platform expands on early technologies that used 5'-end-mutated U1 snRNA," Gunderson explained. "The U1 Adaptor is an oligonucleotide version of this older method and instead targets the 3' end processing step. U1 Adaptors have high activity when used alone and are synergistic when used in combination with RNAi." Gunderson went on to say that the range of possible targets is very broad due to the mechanism of action in which inhibition occurs during the biosynthesis of mRNA at the near universal 3' end processing step. Perhaps the most interesting aspect of this technology is that U1 Adaptors can possibly inhibit genes that do not respond to current RNAi methods.

The applications of U1 Adaptors expand on those currently available using standard RNAi approaches. They can be used as a research tool to determine gene function and to validate gene targets. Gene silencing molecules also have potential prophylactic and therapeutic applications based upon ongoing clinical trials using RNAi and traditional antisense approaches. For some genes that cause disease, these other approaches may not be effective enough and U1 Adaptors may provide a novel solution.'

Source: Rutgers University

Explore further: How calcium regulates mitochondrial carrier proteins

add to favorites email to friend print save as pdf

Related Stories

Thinking small to stop superbugs

Nov 05, 2014

With the help of cutting edge microscopy, new research at U of T Mississauga could help stop "superbugs" in their tracks.

Illuminating the dark side of the genome

Jul 29, 2014

Almost 50 percent of our genome is made up of highly repetitive DNA, which makes it very difficult to be analysed. In fact, repeats are discarded in most genome-wide studies and thus, insights into this part ...

Recommended for you

Dogs hear our words and how we say them

9 hours ago

When people hear another person talking to them, they respond not only to what is being said—those consonants and vowels strung together into words and sentences—but also to other features of that speech—the ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

NeilFarbstein
1 / 5 (1) Feb 08, 2009
I worked on this same concept years ago. One downside is that the SNURP machinery of human cells will be tied up by artificial RNA fragments that will slow down the vital RNA intron editing functions. There are limits to its' effectiveness before toxic effects will occur.
HTTP://VULVOX.TRIPOD.COM

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.